A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality ...

Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...

Dehradun: An Indian pharmaceutical firm, whose products Singapore's Health Sciences Authority (HSA) allegedly issued images ...

The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...

Indian Pharmaceutical Alliance says the study relies on FDA Adverse Event Reporting System data, which captures link between ...

Indian pharmaceutical CDMOs are anticipated to encounter minimal disruptions from the proposed US tariffs of 10-25 per cent.

The Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero.

With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...

New Delhi, A trends study conducted by the federal financial intelligence unit of India has expressed "suspicion" that ...

Industry leaders warn that potential US tariffs on Indian pharmaceutical exports could increase drug costs for American ...